ABPI Scotland: Medicines in Scotland. Membership body of the Pharmaceutical Industry – statutory negotiating body Represents majority of research based.

Slides:



Advertisements
Similar presentations
Healthcare System in Scotland David R Steel Senior Research Fellow, University of Aberdeen Former Chief Executive, NHS Quality Improvement Scotland.
Advertisements

SMALL BUSINESS UPDATE Matthew James Thursday, 19 th May 2005.
“Best Research for Best Health” Andrew Riley Managing Director.
SMC Evaluation Programme. Overview Context Evaluation Programme –Stakeholders –SMC advice Conclusions.
Collaborative Clinical Medicines Procurement (CCMP) “Getting Value for Money” Colette Whigham Category Manager – Pharmacy NHS National Procurement, Scotland.
ABPI Scotland: Medicines in Scotland. Membership body of the Pharmaceutical Industry – statutory negotiating body Represents majority of research based.
The Challenges for Medicines Optimisation
How can the Pharma Industry assist the NHS in constrained times? Can Pharma help with QIPP? PDIG meeting, 10 June 2010 Alison Clough Commercial & Communications.
PROCUREMENT & DISTRIBUTION INTEREST GROUP Autumn Symposium 2007
Patent linkage and the TPP Commercial considerations relevant to TPP 1 Geraldine Storton Hospira Pty Ltd.
An Overview of the Canadian Pharmaceutical Industry
PAHO/WHO Seminar Brasilia October 2002 PAHO/WHO INTERNATIONAL SEMINAR ON CHALLENGES FOR COMPREHENSIVE PHARMACEUTICAL SERVICES BRASILIA, OCTOBER 2002 Experience.
The Pharmaceutical Industry in Europe Key data INDUSTRY (EFPIA Total) (*) Production63,127121,311158,647170,000 (e) Exports23,18089,443144,022170,000.
1 ABPI Vision and Narrative. Clinicians / Commissioners focused on outcomes and incentivised and remunerated on the results they achieve.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Michelle Boudreau, Vice President, Private Markets, March 11, 2015 Presentation to CADA.
Chairman, Pharmaceutical Market Support Group
Health care in GCC NMC Group, UAE.
“Generic Medicines in the Taiwanese and German Legal Systems” 03 June 2011 in Taipei, Taiwan Role of Generics in the German Health Care System Financial.
Improving the competitiveness of the pharmaceutical industry Dominique Limet Senior Vice-President and Area Director Southern and Eastern Europe.
Facts and Figures 2008 Medicines and Health Care The Norwegian Association of Pharmaceutical Manufacturers (LMI)
Public Bodies (Joint Working) (Scotland) Bill. Health and Social Care Integration Not a new concept - policy goal for UK governments over the last few.
Barriers and Facilitators to Clinical Trial Research in Australia Google images Michael Friedlander.
DIGEST OF KEY SCIENCE AND ENGINEERING INDICATORS 2008 Presentation Slides National Science Board.
1 Richard Carter Head of Industry Sponsorship Department of Health London.
1 Investing in Innovation Should the EU do more to match US investment in innovative medicines? Brian Ager EFPIA Gastein, 6 October 2004.
European Supervisory Bodies and Patient Safety Presented by Sandra Eismann (CQC)
Pharmaceutical Overview 1. Pharmaceutical Overview (1) Pharmaceuticals partially covered through various health insurance schemes Public insurance provision.
HTA Regulation and Economic Evaluation in Europe: where are we? Professor Alistair McGuire, LSE, London Istanbul, May 2009.
Todd Hamilton District Sales Manager. Innovation  On average it takes scientists, physicians, engineers, and other researchers between 10 and 15 years.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
DH PRICE CONTROLS Implications for the Future Pricing and Supply of Branded Medicines within NHS Hospitals.
Trevor Single Chief Executive Officer Telecare Services Association United Kingdom.
Barriers to innovation – and solutions The Collaboration Conundrum Colette Goldrick, Director ABPI Northern Ireland.
Robert Hill Consulting What does the future hold? And how can nurse leaders influence it?
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
NHS England New Structure and Industry Engagement Richard Stubbs Head of Commercial and International Innovation NHS England.
Flexicurity and the Danish labour market Facts and figures.
Current Challenges and Future Developments in HTA in the UK Frances Macdonald, 23 rd September 2008 (A personal, Industry View)
Healthcare Improvement Scotland is supporting clinical engagement with NHS board Area Drug and Therapeutics Committees (ADTCs) to develop collaborative.
SAVINGS PROPOSALS 2012/13 CITY & HACKNEY CCG. CONTEXT This report provides information to the Shadow Health & Wellbeing Board on proposed savings in 2012/13.
Delivering Reform: An Industry Perspective Colette Goldrick, Director ABPI Northern Ireland 22 April 2015.
Project no_File reference IMS Health Baltic September 2005 Baltic pharma market 1999 – 2004 Developments, changes and possible future trends.
Innovating out of the recession in the NHS Steve Barnett, Chief Executive NHS Confederation 28 th October 2009 Foundation Trust Network - Primary Care.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Better Care, Lower Costs Value-Driven Health Care Gordon Woodrow Regional Director U.S. Department of Health and Human Services.
PPRS Update Quarter payments 13 th March 2015 David Watson Director Pricing and Reimbursement 1.
Medical Technologies and Pharmaceuticals Industry Growth Centre CHAIR: Dr Bronwyn Evans Presentation Pack June 2015.
The Implementation Plan for Rare Diseases in Scotland abcdefghijklmnopqrstuabcdefghijklmnopqrstu.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
An Introduction to Genetic Alliance UK’s Work in Scotland Natalie Frankish – Development Officer for Scotland Event:Action Duchenne Scottish Conference.
Peterson-Kaiser Health System Tracker What are recent trends in cancer spending and outcomes?
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015 Average annual growth rate of prescription drug spending per capita.
Community Pharmacy in 2016 and beyond: A summary of the Pharmacy Voice response Nanette Kerr Chief Executive Officer Company Chemists’ Association A member.
State Prescription Drug Purchases. Pricing Standards. Initiative Statute. Jeffrey S. Hoch, PhD Professor, Department of Public Health Sciences Associate.
Welcome Lynne Goodacre.  Over view of next 2 days  Overview of internship  Group coaching  Clarity re what they are required to produce by the end.
Scottish Enterprise Denmark’s economy and comparisons with Scotland SE Board performance Committee November 2006.
Peterson-Kaiser Health System Tracker What are the recent and forecasted trends in prescription drug spending?
The pharmaceutical market in Europe
Quality patients value sustainability partnership Value of generic medicines.
Economics of Pharmaceutical Regulation in the Mediterranean: the case of Spain and Italy Joan Costa Font LSE.
Disclosure UK Talking about Transparency.
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
Italy - Evidence package
Disclosure UK Talking about Transparency.
Finland, a Global Testbed for Personalized Cancer Research?
Dispensing Doctors’ Association 20 October 2016
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
RIBGH 2019 Healthcare Summit Kim Keck President & CEO
Presentation transcript:

ABPI Scotland: Medicines in Scotland

Membership body of the Pharmaceutical Industry – statutory negotiating body Represents majority of research based companies Members supply over 90% of medicines to the NHS 2/3 rd of all research and development of new medicines is undertaken by member companies ABPI Code of Practice - administered by PMCPA What is ABPI? 2

Declaration of payments Pads & pens Clinical trial transparency Interaction with patient groups 3 Trust & reputation?

Participation in National groups – SMC, PASAG, PAPIG, LiSAB, Medical Directors group, Strategic Engagement Group, SIGN implementation group, NRS Industry partnership group 2 strategic groups – SAVG, SLSG 9 Therapy specific groups Collaboration - > A Common Understanding 2012 – Working together for Patients 4 ABPI in Scotland

The pharmaceutical industry globally invests more in research and development than any other industry – £12.1 million every day. The pharmaceutical industry employs around 25,000 people in R&D in the UK (Business Enterprise Research and Development (2008, 2009, 2010) 2010 released Nov 2011 – Office for National Statistics (ONS). Investment 5

6

Uptake and innovation Pricing: is it a barrier to uptake? Clinical research: are we under threat? 7 ABPI: Key issues...

Uptake and innovation – Low and slow 8 ABPI: Key issues...

Market share of innovative products in the UK is behind European peers and deteriorating (1)IMS Health World Review Analyst, 2010 (2)OHE analysis 2012 Market share for products -brands and generics- launched in the past 5 years by value (%) (1) NICE’s ~40% rejection rate and NICE ‘blight’ lead to delays and limited access as well as poor performance in innovation uptake (2) 9 Branded medicines launched in the past 5 years are expected to account for 5% of spend only by 2015, similar to previous years’ levels

Uptake of new medicines in Scotland (OHE stats) 10

Scottish Government recognised there is a problem: o CEL 17 (and follow-up CMO) o Statement of Intent o New medicines review (recently announced) Scottish Parliament has recognised there is a problem: o Public Petitions Committee inquiry o Health & Sport Committee Inquiry (ongoing) 11 Uptake of new medicines in Scotland...

Pricing: is it a barrier to uptake? 12 ABPI: Key issues...

Overall, UK spending on medicines as a percentage of GDP (developed countries)… (1) IMS Health World Review Analyst OECD Health Database. All data accessed March 2012 Spending on medicines as a percentage of GDP in various countries in 2011 (1) 13 If Spain cut down pharmaceutical spend by 20%, the proportion of GDP would be 1.2%, i.e. still higher than in the UK’s

The UK has severe uptake issues in critical therapy areas 14 The UK has the lowest per capita spend in cancer medicines launched in the past 5 years (1)IMS Midas 2006 £ Spend per capita on cancer medicines launched in the previous 5 years in Europe (£) (1)

Poor uptake of innovative medicines in the UK leads to poor patient outcomes 15 The UK has the lowest survival rates in cancer in Europe (1)Eurocare year survival rates in cancer in Europe, men and women (%) (1)

Branded pharmaceutical prices are amongst the lowest in developed countries USA190USA176USA183USA252USA281USA331 Germany102Germany106Germany113Germany142Germany155Germany153 UK100UK100Ireland112Ireland134Australia139Australia143 Finland98Ireland99Sweden105Belgium122Ireland133Sweden134 Austria94Finland96Belgium101Finland119Sweden130Belgium123 Netherlands93Austria94UK100Sweden116Belgium122Ireland123 Belgium91Netherlands92Finland99Netherlands115Austria117Netherlands117 France91Belgium90Netherlands99Austria111Italy113Austria115 Italy90Italy90Austria96Spain109Spain106France104 Spain81France84Australia94France108Finland105Finland103 Australia -Spain80France92Italy101France104Italy101 Ireland -Australia -Spain88UK100UK100Spain101 Sweden - -Italy83Australia94Netherlands-UK100 (1) OHE, 11th Report ( ); 5th Report ( ); 2011: OHE calculations based on IMS and PCA data. Note: blank cell = Not available Notes: Table includes the years prior to PPRS negotiations (2003/2004; 2007/2008) as well as for 2010 and 2011 Exchange rate used: Average of Q4 of every year. Position of the UK in the ranking of branded pharmaceutical prices by year (1) 16 In a recent report (September 2012) The European Commission has indicated that the UK is a highly efficient medicines market

The UK has among the highest penetration of and use generics across European countries, c. 65% Source: IMS 2012 (2011 data) Generics market share in Europe by volume % 17 GR 34% BE 35% AT 36% CH 39% IT 40% IE 42% NO 43% ES 45% PT 45% FR 47% FI 49% TK 52% SE 53% NE 63% DK 64% CA 65% DE 65% UK 66% MEAN 49% % GENERIC PRODUCTS % NON GENERIC PRODUCTS

In specific cases, medicines prices drop 90% in price and 95% in volume in the first few years after loss of exclusivity... 18

Total medicines bill for NHSScotland is projected to increase by 2.9% - 3.9% (£1.37bn - £1.43bn) Branded medicines bill for NHSScotland is projected to increase by 0.5% - 1.5% (£0.99bn – £1.03bn) 19 Betweeen 2011 and 2015 ( at list prices - OHE )...

£100m front-line cuts for Scotland’s NHSScotland in Sunday (Nov 25 th 2012) “... On drugs and prescribing, NHS boards claimed many of the savings would accrue by switching from costly branded medicines to generic drugs, no longer covered by commercial patents. “However, they also said reviews were being undertaken by GPs and hospitals to review the volume of prescriptions, the biggest cost driver in recent years.” 20 Volume, not cost as the main driver of rise...?

Clinical research: are we under threat? 21 ABPI: Key issues...

While the pharma sector contributes 1 in 2 R&D pounds in the UK (1), it is in decline % of global sales of leading 100 medicines by country of origin National origin of leading 100 global medicines by sales 2004–2011 (2) 22 Twelve major pharmaceutical site closures between 1996 and 2012 (4) (1)ONS UK Business Enterprise Research and Development, 2009 (2)Department of Health, MISG, Pharmaceutical Industry: Competitiveness and Performance Indicators 2009 (3)Centre for Medicines Research ( Global Clinical Performance Metrics Database; Kinapse report (4)ABPI analysis UK Global Share of patients in clinical trials 2000 – 2010 (3) % % 2% -77%

The UK currently has a prominent position in global launch sequences The UK is an early launch market in global pharmaceutical launch sequences 68% of pharmaceutical companies launch new medicines in the UK first (first, second or third market worldwide) 66% of companies anticipate that government’s proposals for a new pricing scheme will adversely affect the UK’s global position in the launch sequence Source: Industry market research, Feb-March 2012

Evidence given to the Health & Sport Committee inquiry into new medicines from: –a group of 17 oncologists –Oral evidence of a further oncologist –Cancer Research UK: “The UK’s lower rate of uptake for new cancer drugs may be damaging to our ability to design and run internationally competitive studies. If very few patients can get licensed drugs that are the standard of care outside the UK, this could lead to fewer industry-supported trials being conducted in the UK” 24 Don’t just take our word for it...

The future… 25

Harder and more expensive to develop medicines – no more blockbusters… Personalised medicines… Less money, more patients… –Health & social care integration –Long term conditions –Move away from acute care The future… 26

Access to new medicines reviews… –Barriers to access? Closer collaboration and partnership working…? The future… 27

Thank you… Keith Small – 28